Maze Therapeutics, Inc. (MAZE) stock
MAZENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$31.20−1.67 (-5.08%)
Close on Nov 18, 2026Market cap $1.73BP/E –Yield –
Maze Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Maze Therapeutics's revenue for the twelve months ending Dec 31, 2024 was $167.50M. For fiscal 2024 it was $167.50M.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $167.50M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $0 | -100.0% |
| Q1 FY2026 | Mar 31, 2026 | $20.00M | -87.9% |
| Q2 FY2025 | Jun 30, 2025 | $0 | – |
| Q4 FY2024 | Dec 31, 2024 | $0 | – |
| Q3 FY2024 | Sep 30, 2024 | $2.50M | – |
| Q2 FY2024 | Jun 30, 2024 | $165.00M | – |
See a number that looks wrong?